Colorectal cancer

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

This week in drug discovery (22-26 January) 

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal,… Read More

#News

Colorectal cancer
#AACR #Cancer research #Cardiff Oncology #Clinical trials #Colorectal cancer #KRAS

Promising data for onvansertib in combination with standard-of-care  

Findings from Cardiff Oncology’s Phase Ib portion of the Phase Ib/II study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC) have been published in Clinical Cancer Research, a journal of the American Association for Cancer Research.  The publication underscores the safety… Read More

#Cancer Research #News

Business agreement
#Colorectal cancer #Inspirna #License agreement #Merck #Oncology #Phase II trial

Merck expands colorectal cancer portfolio with ompenaclid

Merck has agreed a deal with Inspirna for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8 and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC). “Over the past… Read More

#Business & Investment #News

Genetics
#AACR 2023 #Cancer research #Colorectal cancer #Genetics / genomics #Oncology

Patients of African heritage have fewer actionable mutations

Genomic profiling of patients who were treated for colorectal cancer showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry. These patients were also less likely to qualify for treatment with immunotherapy, according to data presented at the AACR Annual Meeting… Read More

#Cancer Research #News #Trending News

Colon cancer
#Cancer research #Cardiff Oncology #Clinical trial #Colorectal cancer #Oncology #Phase II trial

Metastatic colorectal cancer trial launches in the US

A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC)… Read More

#Cancer Research #News

Colorectal Cancer Awareness Month
#Cancer research #circular RNAs #Colorectal cancer #Immuno-oncology #Immunotherapy #Oncology

Colorectal Cancer Awareness Month: Drug discovery innovation

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Held in the US March every… Read More

#Cancer Research #Exclusive Content

Colorectal cancer cells
#Cancer research #Chemotherapy #Chemotherapy-resistance #Colorectal cancer #Oncology #Tyrosine kinase inhibitors

Targeted cancer drug overcomes chemotherapy resistance

A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer.  The team successfully used a combination of tyrosine kinase inhibitors, opening up new avenues for developing therapies that are more targeted than chemotherapy.  Colorectal cancer is… Read More

#Cancer Research #News #Trending News

#Alzheimer's #Cancer research #Colorectal cancer #Drug discovery #Eczema #FDA #Plaque Psoriasis

This week in drug discovery (12-16 September)

News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. … Read More

#News

Colorectal cancer
#Cancer research #Colorectal cancer #Oncology

Trial sheds light on combined treatment for colorectal cancer

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone. The Phase III clinical trial studied participants with… Read More

#Cancer Research #News